Search results

EraCal Therapeutics Ltd. develops a oral-active anti-obesity drug, a first-in-class appetite suppressor. This new chemical entity emerged from EraCal’s drug discovery platform, which also forms the basis of a research collaboration with Novo Nordisk.

Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug manufacturing and digital health investment.

Being a Swiss technology innovation center we develop and transfer advanced technologies to the industrial sector. We are a non-profit orientated, public-private organization and collaborate with scientific and research institutes, and industrial partners. CSEM is active all over Switzerland.

Clinical-stage biotech company developing next-generation allosteric therapies. Its candidate, GT-02287, is in P1b trials for PD with potential in other neurodegenerative and lysosomal storage disorders. The pipeline also includes preclinical programs targeting metabolic diseases and solid tumors.

Artidis® is a pioneering clinical stage health technology company that aims to set the gold standard in tissue analysis and therapy optimization. Artidis focuses its efforts on solid tumors to enhance responses to chemo, immuno, and cell therapies, driving precision in cancer care.

abc biopply AG is pioneering NAM technologies and organoid CRO services that boost in vitro studies for drug discovery and development to IND relevance using its proprietary 3D CoSeedis Multi-Organoid in chip Technology™ on clinically relevant disease models (oncology, neurology, obesity and others)

SunRegen is a biopharmaceutical company with a mission to develop drugs to treat neurodegenerative diseases.

Selective mode antimicrobial resistance therapeutics Selmod is a startup with a mission dedicated to the development of disruptive antibacterial and antifungal therapies needed to address the critical unmet need for antimicrobial resistance. Focus on high revenue segment - patients in hospitals.

TargImmune Therapeutics AG is a private Swiss-based biotechnology company focused on drug development using novel targeted onco-immunotherapies.

There is a new kit on the block. Swiss start-up NEMIS Technologies AG specialises in the development of simple, safe, and on-site pathogen testing solutions. Its detection test for Listeria monocytogenes is already commercially available in Switzerland, France, and Spain.

IPS Biopharma AG is pioneering interventional immuno-oncology by transforming standard-of-care tumor ablations into a powerful immunotherapy against metastatic cancers. Our technology induces a tumor-specific immune response from thermally liberated tumor antigens to eliminate the cancer.

We provide our clients, however complex their challenges may be, with effective and high quality solutions throughout the life cycle of their products and the evolution of their company.

HAYA Therapeutics is a precision therapeutics company that discovers and develops innovative tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging, including cancer.

Swiss-based Life Sciences consultancy and part of the athagoras Group. We enable European market access for pharma & biotech, combining strategy, evidence generation and HTA expertise, from valuation and trial design to reimbursement, JSC, JCA and pricing negotiations.

iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families.

Experts in Life Science products Witec AG is your innovative Swiss Partner for Life Science Products since 1988. We deliver cutting-edge instruments and consumables backed by exceptional, agile service and an unwavering commitment to accelerating your research.

Since over 20 years, Xenometrix produces bioassays for preclinical or environmental screening in the field of toxicology (in vitro), of endocrine disruptor chemicals or ex vivo skin for skin absorption studies. Service analytics is offered to pharmaceutical, chemical, cosmetic industries.

Wyss Zurich is a joint accelerator of ETH & University of Zurich. Our mission is to drive the clinical translation of outstanding scientific discoveries into new therapies for patients and innovations in the fields of regenerative medicine and robotics, and hybrid technologies in these fields.

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct.

Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.

TOLREMO engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug-resistance therapies.

At UCB, we are inspired by patients and driven by science. Our strategy: to offer value to people suffering from severe diseases in neurology and immunology. In Switzerland, UCB invested around 700 million CHF in his plant for industrial equipment on the cutting edge of technology and innovation.

Synple Chem was founded to develop new easy to use automated laboratory equipment for chemistry research labs.

Tepthera is a spin off from the ETH Zurich focusing on product development in the field of cancer immunotherapy, autoimmune- and infectious diseases.

SpacePharma provides researcher, institutes and commercial companies an easy and affordable access to the microgravity environment. Our novel technology enables researchers to perform complex chemical and biological experiments with our proven cutting-edge remote-control technology and labs in space.

SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 750 institutions in over 70 countries.  Our network advances data-driven medicine to improve health outcomes and economics worldwide.

Securecell is an innovator for both the biotech and medtech space. Developing use-case applications for automated bioprocessing and smart pharmacoligical facilities, as well as the transformative applications of digital technologies to help hospitals and life scientists solve next-world problems.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need.

Regen Lab is a global leader in products for autologous regenerative medicine based on freshly prepared platelet rich plasma from the patient’s own blood, used either alone or combination with hyaluronic acid or other fresh autologous cells from the patient’s fat or bone marrow.

As Swiss branch of Promega Corp, Promega AG offers local scientific expertise for 4000+ products covering genomics, proteomics and cell analysis. Promega is a global leader in providing innovative solutions for drug discovery, basic research, human identification, diagnostics and food/water testing.

We develop complex dosage forms enabling early market entry generic drugs and innovative supergeneric products. We deal with licensing-out to leading Pharma partners worldwide for market access.

PeptART manufactures a large variety of amino acid derivatives, pseudoprolines, and peptides on-site in our facility in Switzerland. We deliver our products from a few grams up to several tens of kg worldwide. Trust builds on quality and expertise – PeptART – Your Swiss pARTner in Peptide Chemistry.

Oculis is a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Headquartered in Switzerland, Oculis is led by an experienced management team and supported by leading international healthcare investors.

Oculox Technologies is a medical device company focused on the application of state-of-the art micro and laser technology in the field of medical diagnostics and therapy.

We specialize in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH technology platform, we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind.

OMNI Life Science GmbH is located in Basel, Switzerland. We are your local partner for solutions in cell-based assays and are dedicated to provide innovative solutions for research in life science.

Novigenix is a Swiss precision medicine company specialized in ImmunoTranscriptomic solutions for the detection of disease, therapy optimization, and disease recurrence monitoring to improve disease management and patient outcomes.

Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

Novaremed AG, a privately held clinical-stage biopharmaceutical company, is innovating chronic pain management through the development of effective and safe treatment options as an alternative to opioids. HQ Basel (Switzerland); subsidiaries Novaremed Ltd (Israel) & Metys Pharmaceuticals (CH).

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Novassay is a biotech active in the area of Ion Channel therapeutics with focus in neuropathic pain and Oncology. We have a portfolio of assets currently in development (approaching IND stage) and interested in partnering and R&D collaborations.

Novimmune SA has brought 7 monoclonal antibodies to clinical development stage, one of which, Emapalumab, has been approved by the FDA in 2018. We now focus on our bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.

NBE-Therapeutics engages in the development of “next-generation”, antibody drug conjugates (ADCs) with the objective to develop first-in-class ADC product candidates until clinical proof-of-concept in patients. NBE Therapeutics is part of the Boehringer-Ingelheim group.

Memo Therapeutics AG develops therapeutic antibodies for viral infections and cancer. Lead asset potravitug targets BKV in kidney transplant recipients; Phase II SAFE KIDNEY data, presented in Nov 2025, support a planned Phase III start in 2026. MTx is also building an oncology discovery pipeline.

MetrioPharm AG, a clinical stage biopharmaceutical development company based in Zurich with a subsidiary in Berlin, Germany, has developed a platform of small molecule drug candidates (oral and i.v.) which targets the modulation of immune cell metabolism without suppressing the immune system.

Microsphere (MS) is a CDMO focused on new developments, cGMP manufacturing, R&D, analytical and regulatory support. MS is able to address complex challenges, including formulations for poorly water-soluble drugs, considering the extensive expertise in Spray Drying and Capsule Filling.

LubioScience is the biggest lifescience reagents & services platform in Switzerland. Representing some of the world’s most recognized brands, we provide over 5 million products from more than 120 suppliers and pride ourselves in working with most Swiss biotech companies & start-ups.

Lunaphore has developed an innovative device for cancer tissue diagnostics. Its award-winning technology based on microfluidics aims to achieve faster & more precise results than current techniques. It was founded in 2004 with the vision of bringing –omics like approaches to tissue diagnostics. Lunaphor

Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile populations, e.g. children, cancer patients and the elderly, who may be already on multiple medications.

LimmaTech Biologics AG is a Swiss clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to protect from the increasing threat of global microbial infections due to emerging antimicrobial resistance (AMR) and sexually transmitted diseases.

Life Technologies Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community.

Laves-Arzneimittel GmbH has focused on the exploration and development of preparations based on the probiotic Escherichia coli strain Laves discovered in 1931 by Dr. Wolfgang Laves.

Kinematica is a mechanical engineering company from Lucerne. We have our expertise in the field of homogenization and dispersion equipment form lab to production scale. We focus on close collaboration with our customer to built and scale equipment on request - for homogenization perfected.

Based on the liposomal technology platform, InnoMedica has built a diversified pipeline with lead compounds in oncology and neurodegenerative diseases. Clinical trials for the treatment of breast cancer as well as Parkinson's disease are conducted in Swiss hospitals.

InterAx developed a unique drug discovery platform integrating biochemistry, cellular pathways mathematical modelling and AI to decode the cellular communication language. This novel approach enables the rapid and precise identification of differentiated effective and safe candidates.

InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding healthy and diseased human physiology in vitro.

ImmunOs Therapeutics AG is a biotechnology company focused on discovering and developing novel human immunomodulatory proteins for cancer with a specific role in innate immunity.

IBR Inc. is a GxP-compliant CRO offering advanced bioanalytical services for pre-clinical and clinical development of antibodies, biologics, biosimilars, antibody-drug conjugates and vaccines. The services include bioanalytics for product release under GMP.

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients.

Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology.

Calliditas is a commercial stage biopharmaceutical company focused on novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. In 2021, Calliditas acquired Genkyotex, specializing company in NOX therapies, French & Swiss based.

Our R&D center for biologics in Switzerland has end-to-end capabilities to discover Novel Biological Entities (NBEs) and develop them from inception through to pre-clinical & clinical studies. It is also fully equipped to manufacture clinical trial-size batch materials.

GMT Fine Chemicals SA is a Swiss company founded in 1998 based in Couvet (Neuchâtel). The company has been designed to allow the chemical synthesis of Active Pharmaceutical Ingredients (API) under conditions guaranteeing the quality of the products (GMP). Products are sold world-wide (EU, USA, JPN).

EspeRare is an ethical non-profit biotech. It combines pharmaceutical know-how and philanthropic and public investments to bring to life treatments that have been abandoned by the pharmaceutical industry. EspeRare represents an affordable alternative to the high cost innovation of medicines.

evitria specializes in CHO-based transient expression of recombinant proteins, with a focus on antibodies—including bispecific, Fc-silenced, and afucosylated formats. With over 100,000 transfections, we are a trusted partner for biotech and pharma worldwide.

EffRx Pharmaceuticals SA is a commercial-stage pharmaceutical company, based in Switzerland, that develops and commercializes prescription medications for specialty indications. The primary focus is on therapeutics for men and women with musculoskeletal, genitourinary and rare diseases. Abiogen Pharma acquire

CSL (ASX:CSL; USOTC:CSLLY) – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – is a global biotechnology leader that develops and delivers innovative lifesaving medicines, protects public health and helps people with life-threatening medical conditions live full lives.

Curatis acquires, licences, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and speciality diseases in Switzerland. We have a promising pipeline of novel speciality care and orphan drugs for neurological disorders

CRB is a leading design, construction and consulting firm serving life sciences companies globally since 1984. From small studies to execution of complex projects, we have the expertise to deliver solutions to our clients in the local pharmaceutical and biotechnology market.

We develop ADCs and radioligands, leveraging our conjugation platform. We create new treatments offering hope to patients that suffer from aggressive cancer with poor prognosis.

Celonic is a “Pure Play” Biologics CDMO with a focus on CHO-based expression systems. Celonic is a pioneer in using next generation bioprocessing technologies and has a state-of-the-art Biologics Development Center in Switzerland, with clinical and commercial GMP manufacturing facilities in Germany.

With over 40 years in the pharmaceutical industry, Cerbios is a privately held company with headquarter in Barbengo-Lugano, Switzerland, specialising in the development and manufacture of both chemical and biological APIs for its partners worldwide.

BÜHLMANN designs, develops, manufactures and sells worldwide innovative medical diagnostic products and kits (IVD or RUO) in inflammation, cellular allergy, neuroimmunology, clinical chemistry, chronobiology and others.

Bromatech has been engaged for more than 25 years in the study and development of targeted food supplements based on specific strains of lactic acid bacteria, antioxidants and essential fatty acids which are able to interact with the precious heritage of the human microbiota.

Catalent is the global leader in enabling pharma, cell & gene therapy and biopharma partners to optimize product development, launch, and full life-cycle supply for patients around the world. Catalent helps accelerate over 1,000 partner programs every year for partners of all sizes.

Securing life sciences supply chains. Complex chemicals, peptides and key biologics: products, services and innovation. Biosynth is a supplier of critical materials with chemicals on the milligram to ton scale, with peptides at mg to multikilogram scale. ISO 9001 and GMP facilities.

BioArk drives innovation and business growth from early stages to commercialization. With two technology parks in Valais and over 10,000 jobs, our ecosystem offers cutting-edge facilities, expert coaching, funding support, and a strong industrial and scientific network.

We at Bioengineering AG design and build customized equipment to improve bioproduction efficiency in biotech, novel food, and biopharma plants. Our engineering teams develop reliable bioreactors and fermenters, from lab scale to production, for clients worldwide. Trusted for over 50 years.

At Biogen, we develop, market and manufacture therapies for people living with serious neurological, autoimmune and rare diseases.

Baliopharm AG, is a biotechnology company focusing on the development of innovative therapeutics for the treatment of chronic liver diseases, immune mediated inflammatory diseases, as well as for cancer.

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) is a commercial-stage biopharmaceutical company headquartered in Switzerland. Basilea is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections.

At BD, we are committed to sustainable healthcare. We are inspired by childhood to be innovative thinkers, to be ambitious in our ways of caring about the patients and healthcare professionals of tomorrow.

Bio-Rad Laboratories continues to play a leading role in the advancement of scientific discovery by offering a broad range of innovative tools and services to the life science research and clinical diagnostics markets.

Anaveon is a global clinical stage biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. Our team is driven to make this vision a reality: we are committed to transforming immunological insights into life-changing therapies.

Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, including orphan tauopathies, Alzheimer’s and Parkinson’s disease.

ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

Swiss health science co. pioneering clinically proven products to promote cellular health and longevity. The company’s proprietary nutrient, Mitopure, is clinically shown to combat age-related declines in mitochondrial health and muscle function. Nestlé Health Science is a global strategic partner.

AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs.

AC Immune SA is a clinical-stage biopharma that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and NeuroOrphan indications. The Company has two clinically validated technology platforms, SupraAntigen® and Morphomer®.

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders.